ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0891

Serum Potassium Changes in US Veterans Receiving Patiromer with Dialysis-Dependent ESKD and Hyperkalemia

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Kovesdy, Csaba P., The University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Gosmanova, Elvira O., Albany Medical College, Albany, New York, United States
  • Woods, Steven D., Vifor Pharma, Inc., Redwood City, California, United States
  • Rowan, Christopher G., COHRDATA, San Clemente, California, United States
  • Hansen, Jared, Salt Lake City VA Medical Center (IDEAS), Salt Lake City, Utah, United States
  • Sauer, Brian C., Salt Lake City VA Medical Center (IDEAS), Salt Lake City, Utah, United States

Patiromer is a sodium-free, non-absorbed, potassium (K+)-binding polymer approved for the treatment of hyperkalemia (HK). This retrospective cohort study aimed to describe serum K+ changes in Veterans with HK and end-stage kidney disease (ESKD) receiving dialysis who initiated patiromer.


Serum K+ concentrations were evaluated pre- and post-patiromer initiation using the National VA Corporate Data Warehouse (1/1/16–8/31/18). Changes in mean serum K+ concentration were compared at 1, 3, and 6 months following first patiromer dispensing (index date) using the paired t-test (pre K+ versus post K+). All patients had a baseline K+ ≥5.1 mEq/L and ESKD. Patients with continuous exposure to patiromer were analyzed. Follow-up began on the index date and ended at first censoring event (discontinuation or switch of index K+ binder, death, end of follow-up, or 6 months post-index).


98 patients with ESKD requiring dialysis and HK initiated patiromer. Patient characteristics at baseline were median age 66 years, African-American race 39%, diabetes 71%, heart failure 40%, and mean K+ value of 6.1 mEq/L (standard deviation = 0.7). The initial dose of patiromer was 8.4 g in 96% of patients with few observed increases in unit dose during the follow-up period. Following patiromer initiation, statistically significant reductions in serum K+ concentration were observed at 1 month (–1.24 mEq/L), 3 months (–1.15 mEq/L), and 6 months (–1.36 mEq/L; Figure).


Among dialysis-dependent US Veterans with HK, patiromer was associated with clinically relevant reductions in serum K+ concentrations at all study time points. These findings warrant additional investigation in a larger dialysis cohort with HK.


  • Commercial Support